Denali Therapeutics (DNLI) Profit After Tax (2017 - 2024)
Historic Profit After Tax for Denali Therapeutics (DNLI) over the last 8 years, with Q4 2024 value amounting to -$114.8 million.
- Denali Therapeutics' Profit After Tax rose 395.07% to -$114.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.8 million, marking a year-over-year decrease of 19111.79%. This contributed to the annual value of -$422.8 million for FY2024, which is 19111.79% down from last year.
- Per Denali Therapeutics' latest filing, its Profit After Tax stood at -$114.8 million for Q4 2024, which was up 395.07% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' Profit After Tax's 5-year high stood at $244.9 million during Q4 2020, with a 5-year trough of -$119.5 million in Q4 2023.
- Moreover, its 5-year median value for Profit After Tax was -$79.9 million (2021), whereas its average is -$55.7 million.
- In the last 5 years, Denali Therapeutics' Profit After Tax surged by 55328.09% in 2020 and then plummeted by 15399.96% in 2024.
- Quarter analysis of 5 years shows Denali Therapeutics' Profit After Tax stood at $244.9 million in 2020, then tumbled by 130.73% to -$75.3 million in 2021, then tumbled by 31.11% to -$98.7 million in 2022, then decreased by 21.07% to -$119.5 million in 2023, then increased by 3.95% to -$114.8 million in 2024.
- Its Profit After Tax was -$114.8 million in Q4 2024, compared to -$107.2 million in Q3 2024 and -$99.0 million in Q2 2024.